Omission of surgical treatment
ProcedureOmission of surgery in patients with pCR after neoadjuvant chemotherapy and negative VABB biopsy
NCT Number: NCT06281210
This single arm study aims to evaluate the efficacy and safety of a non-surgical approach, consisting of radiotherapy (RT) alone, for patients who have achieved a complete pathological response (pCR) following neoadjuvant chemotherapy (NACT). The study design involves the histological confirmation of pCR using vacuum-assisted biopsy (VABB) or vacuum-assisted excision (VAE) guided by ultrasound. The primary objective is to demonstrate that the non-surgical, RT-only treatment and follow-up approach is not inferior to the traditional surgical approach in patients with pCR after NACT.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Istituto di Candiolo IRCCS, Candiolo, Turin, Italy
Neoadjuvant chemotherapy (NACT) in breast cancer is considered the "gold standard" for the treatment of locally advanced and inoperable malignancies.
In recent years, in view of the evidence gathered, it has also become a conventional treatment alternative for patients with operable disease who are possible candidates for adjuvant chemotherapy. NACT thus aims to reduce mortality and increase surgical options, while at the same time allowing in vivo chemosensitivity testing. In view of this, NACT represents the ideal setting for clinical and translational research, which nowadays also has to address the question of future treatment options.
It is indeed a source of lively debate whether chemotherapy should be considered the only possible treatment option for the patient.
This study falls into this context, the innovative aim of which is to demonstrate histologically with the use of VABB, the complete pathological response (pCR) and to avoid surgery.
The main aim of this study is to show that a non-surgical, radiotherapy-only treatment and follow-up approach is not inferior to a surgical approach for patients who have shown complete pathological response (pCR) following neoadjuvant chemotherapy (NACT), as confirmed through histological analysis of imaging-guided sampling.
Histology will be performed by sampling 4 grams of tissue by vacuum-assisted biopsy (VABB) or vacuum-assisted excision (VAE) by ultrasound guidance (on breast marker).
The hypothesis of the study is that the VAE/VABB will be used in patients with pCR at post-NACT imaging to demonstrate the absence of disease in the previous tumour bed and, accordingly, that the use of VAE/VABB with negative histology would lead to a gold standard of treatment without surgical overtreatment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Omission of surgery in patients with pCR after neoadjuvant chemotherapy and negative VABB biopsy
Time frame: 5 years
Absence of disease recurrence or progression, second primary tumor, or death
Time frame: 6 months
Evaluation of the accuracy of breast MRI in predicting pCR following NACT
Time frame: 6 months
Evaluation of the accuracy of breast CEM in predicting pCR following NACT
Contact information is provided by the study sponsor or research team.
European Institute of Oncology
Other
Non-inferiority Study in Patients With Complete Pathological Response After Neoadjuvant Chemotherapy and Negative VABB Biopsy Undergoing RT Alone, Omitting Surgical Treatment
Acronym: BETTY-CRASY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06220214
Breast Cancer, Breast Diseases
Stony Brook, New York, United States
View Trial DetailsNCT04585750
Adnexal Diseases, Advanced Malignant Neoplasm
Irvine, California, United States
View Trial DetailsNCT04030507
Breast Cancer, Breast Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT05020860
Breast Cancer, Breast Cancer Female
Houston, Texas, United States
View Trial Details